RPID — Rapid Micro Biosystems, Inc.

Is RPID overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of August 19, 2026

Rapid Micro Biosystems, Inc. (RPID) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $1.56. The rating moved from Overbought to Oversold on August 8, 2026.

See all oversold Healthcare stocks →

AI analysis

Rapid Micro offers differentiated rapid microbial detection solutions positioned to benefit from rising biologics and CDMO demand; recurring consumables and service revenue could drive margin improvement as installed base grows. Near‑term performance will hinge on continued commercial adoption, pace of customer validations, and ability to extend consumable/service penetration. Financially, the company is still loss‑making with financing risk that could pressure equity if growth lags. Key near‑term catalysts include new customer wins, expanded CDMO partnerships, and stronger consumables attachment rates; failure to convert pilot installs into recurring revenue or the need for dilutive capital would materially worsen the outlook.

Key factors

  • Addressable market exposure to biologics, CDMO and fill/finish suppliers benefiting from a multi‑year biologics and specialty therapeutics manufacturing upcycle
  • Proprietary rapid microbial detection and identification technology that can shorten release cycles and reduce manufacturing bottlenecks versus traditional sterility testing
  • Early commercial traction with pharmaceutical and biotech customers and recurring consumables/service revenue potential
  • Sector themes supportive of demand: growing biologics/GLP‑1 manufacturing, expanded diagnostics/screening emphasis, and CDMO outsourcing trends
  • Current valuation is low in absolute terms, leaving upside if execution and adoption accelerate
  • Operational focus on driving path to consistent revenue growth and margin expansion via product installs, consumables, and service contracts

Risks

  • Limited cash runway and history of operating losses that could require dilutive financing if revenue growth does not accelerate
  • Customer adoption risk: long qualification/validation cycles in regulated manufacturing environments can delay purchase timing and revenue recognition
  • Competition from incumbent sterility testing workflows, established diagnostics suppliers, and alternative rapid-testing entrants
  • Regulatory and validation hurdles: customers and regulators require substantial validation for any change to sterility/contamination testing protocols
  • Low stock liquidity and potential for outsized short‑term volatility; investor sentiment can swing sharply on execution or funding news
  • Customer concentration or dependence on a handful of early adopters could impact results if contracts are delayed or lost

See today's live rating, score and targets

Members see the live hourly rating for RPID — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.